130 related articles for article (PubMed ID: 32897733)
1. Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort.
Somashekhar SP; Zaveri S; Vijay DG; Dattatreya PS; Kumar R; Islahi F; Bahl C
JCO Glob Oncol; 2020 Sep; 6():1363-1369. PubMed ID: 32897733
[TBL] [Abstract][Full Text] [Related]
2. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
[TBL] [Abstract][Full Text] [Related]
3. Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.
Soliman H; Flake DD; Magliocco A; Robson M; Schwartzberg L; Sharma P; Brown K; Wehnelt S; Kronenwett R; Gutin A; Lancaster J; Cuzick J; Gradishar W
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914026
[TBL] [Abstract][Full Text] [Related]
4. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
Constantinidou A; Marcou Y; Toss MS; Simmons T; Bernhisel R; Hughes E; Probst B; Meek S; Kakouri E; Georgiou G; Zouvani I; Savvidou G; Kuhl V; Doedt J; Wagner S; Gutin A; Slavin TP; Lanchbury JS; Kronenwett R; Ellis IO; Rakha EA
Clin Cancer Res; 2022 Oct; 28(20):4435-4443. PubMed ID: 36043530
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
Penault-Llorca F; Dalenc F; Chabaud S; Cottu P; Allouache D; Cameron D; Grenier J; Venat Bouvet L; Jegannathen A; Campone M; Debled M; Hardy-Bessard AC; Giacchetti S; Barthelemy P; Kaluzinski L; Mailliez A; Mouret-Reynier MA; Legouffe E; Cayre A; Martinez M; Delbaldo C; Mollon-Grange D; Macaskill EJ; Sephton M; Stefani L; Belgadi B; Winter M; Orfeuvre H; Lacroix-Triki M; Bonnefoi H; Bliss J; Canon JL; Lemonnier J; Andre F; Bachelot T
ESMO Open; 2024 May; 9(5):103443. PubMed ID: 38692082
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
[TBL] [Abstract][Full Text] [Related]
7. First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
Ettl J; Anders SI; Hapfelmeier A; Paepke S; Noske A; Weichert W; Klein E; Kiechle M
Arch Gynecol Obstet; 2020 Dec; 302(6):1461-1467. PubMed ID: 32902674
[TBL] [Abstract][Full Text] [Related]
8. Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer.
Klein E; Kiechle M; Josipovic A; Anders SI; Noske A; Mogler C; Hapfelmeier A; Ettl J
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38722442
[TBL] [Abstract][Full Text] [Related]
9. Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
Penault-Llorca F; Kwiatkowski F; Arnaud A; Levy C; Leheurteur M; Uwer L; Derbel O; Le Rol A; Jacquin JP; Jouannaud C; Quenel-Tueux N; Girre V; Foa C; Guardiola E; Lortholary A; Catala S; Guiu S; Valent A; Boinon D; Lemonnier J; Delaloge S
Breast; 2020 Feb; 49():132-140. PubMed ID: 31790959
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Blank PR; Filipits M; Dubsky P; Gutzwiller F; Lux MP; Brase JC; Weber KE; Rudas M; Greil R; Loibl S; Szucs TD; Kronenwett R; Schwenkglenks M; Gnant M
Pharmacoeconomics; 2015 Feb; 33(2):179-90. PubMed ID: 25404424
[TBL] [Abstract][Full Text] [Related]
11. The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER
Mokbel K; Wazir U; Wazir A; Kasem A; Mokbel K
Anticancer Res; 2018 Aug; 38(8):4747-4752. PubMed ID: 30061244
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer.
Mokbel K; Wazir U; El Hage Chehade H; Manson A; Choy C; Moye V; Mokbel K
Anticancer Res; 2017 Dec; 37(12):6863-6869. PubMed ID: 29187466
[TBL] [Abstract][Full Text] [Related]
13. EndoPredict
Almstedt K; Mendoza S; Otto M; Battista MJ; Steetskamp J; Heimes AS; Krajnak S; Poplawski A; Gerhold-Ay A; Hasenburg A; Denkert C; Schmidt M
Breast Cancer Res Treat; 2020 Jul; 182(1):137-146. PubMed ID: 32436145
[TBL] [Abstract][Full Text] [Related]
14. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.
Fallowfield L; Matthews L; May S; Jenkins V; Bloomfield D
Psychooncology; 2018 Apr; 27(4):1264-1269. PubMed ID: 29448311
[TBL] [Abstract][Full Text] [Related]
15. Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
Jank P; Lindner JL; Lehmann A; Pfitzner BM; Blohmer JU; Horst D; Kronenwett R; Denkert C; Schmitt WD
Breast Cancer Res Treat; 2022 Jan; 191(2):327-333. PubMed ID: 34783927
[TBL] [Abstract][Full Text] [Related]
16. Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.
Villarreal-Garza C; Lopez-Martinez EA; Deneken-Hernandez Z; Maffuz-Aziz A; Muñoz-Lozano JF; Barragan-Carrillo R; Ramos-Elias P; Moreno B; Diaz-Perez H; Peña-Curiel O; Curiel-Valdez JJ; Bautista-Piña V
PLoS One; 2020; 15(3):e0228884. PubMed ID: 32160201
[TBL] [Abstract][Full Text] [Related]
17. Impact of EPclin on adjuvant therapeutic decision making and comparison of EPclin to the PREDICT tool.
Bourien H; Quillien V; Godey F; Perrin C; Le Du F; Guillermet S; Blanchot J; Lavoué V; Campillo-Gimenez B; Brunot A; Crouzet L; De la Motte Rouge T; Diéras V; Lefeuvre-Plesse C
Int J Biol Markers; 2021 Jun; 36(2):57-63. PubMed ID: 34027694
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.
Noske A; Anders SI; Ettl J; Hapfelmeier A; Steiger K; Specht K; Weichert W; Kiechle M; Klein E
Breast; 2020 Feb; 49():101-107. PubMed ID: 31786414
[TBL] [Abstract][Full Text] [Related]
19. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
20. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
